- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07850128
Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection
Risk of Cervical Cancer Following Incident, Persistent and History-unknown Human Papillomavirus (HPV) Detection by HPV Genotype
The goal of this register-based retrospective observational study is to understand the risk of cervical cancer following incident, persistent and history-unknown HPV detection by HPV genotype in healthy women participating in HPV-based cervical screening. The main questions it aims to answer are:
- Whether an incident HPV detection with certain HPV genotypes has low risk of cervical cancer in 3 to 5 years thus does not need further clinical assessment before the next screening test?
- How risky a persistent HPV detection is, and whether persistent detection of any high-risk HPV genotype warrant immediate clinical assessment?
- How risky a HPV detection is, if no previous HPV test result is available?
As being a register-based retrospective observational study, study subjects will not be asked to do any specific task for this study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study includes all women in the study population (women at screening ages and living in the Stockholm region during 2014-2023) who had HPV positive test result(s) in the primary HPV screening. In 2014-2016, half of the screening population were randomised to primary HPV screening and the other half received cytology-based screening (NCT01511328). From 2017 onwards, all women received primary HPV screening. As data are retrieved from established registries which are already accessible to the researchers for previous and ongoing related research projects, the data collection time is almost negligible.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jiangrong Wang, PhD
- Numéro de téléphone: +46769309451
- E-mail: jiangrong.wang@ki.se
Sauvegarde des contacts de l'étude
- Nom: Joakim Dillner, PhD
- E-mail: joakim.dillner@ki.se
Lieux d'étude
-
-
-
Stockholm, Suède, 141 52
- Recrutement
- Centre for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet
-
Contact:
- Jiangrong Wang, PhD
- Numéro de téléphone: +46769309451
- E-mail: jiangrong.wang@ki.se
-
Contact:
- E-mail: jiangrong.wang@ki.se
-
Sous-enquêteur:
- Jiangrong Wang, PhD
-
Chercheur principal:
- Joakim Dillner, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in the primary HPV test during 2014-2023
La description
Inclusion Criteria:
- Women living in the Great Stockholm Region in Sweden, at cervical screening ages (age 22-70 years), and having had an HPV positive result in primary HPV test during 2014-2023
Exclusion Criteria:
- Women without valid personal identity number in the population registry
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: RETROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Incident HPV detection
The first HPV positive result in the primary HPV test, following an HPV negative test result in the previous primary HPV test |
All data will be retrieved retrospectively from registry data. |
|
Persistent HPV detection
The HPV positive result in the primary HPV test following an HPV positive test result with the same genotype in the previous primary HPV test |
All data will be retrieved retrospectively from registry data. |
|
History-unknown HPV detection
The first HPV positive result in the primary HPV test, without any primary HPV test record in the past |
All data will be retrieved retrospectively from registry data. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diagnosis of invasive cervical cancer
Délai: From HPV infection to the end of the study Dec 31st, 2024
|
Primary and invasive cervical cancer |
From HPV infection to the end of the study Dec 31st, 2024
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Precancerous lesion CIN2+ (Cervical Intraepithelial Neoplasia grade 2 and above)
Délai: From HPV infection to the end of the study Dec 31st, 2024
|
CIN2, CIN3, Adenocarcinoma in situ |
From HPV infection to the end of the study Dec 31st, 2024
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Bjorge T, Stoer NC, Hverven SK, Nygard M, Trope A, Engesaeter B. Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study. Int J Cancer. 2025 Jul 15;157(2):251-259. doi: 10.1002/ijc.35359. Epub 2025 Feb 8.
- Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024 Aug 3;404(10451):435-444. doi: 10.1016/S0140-6736(24)01097-3.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Processus pathologiques
- Attributs de la maladie
- Infections
- Maladies virales
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections par le virus de l'ADN
- Infections virales tumorales
- Conditions pathologiques, signes et symptômes
- Infections à papillomavirus
Autres numéros d'identification d'étude
- IPUHPV&CxCa
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
IPD will be derived from the Swedish National Cervical Screening Registry and the Swedish National Quality Register for Gynaecological Cancers. Data from these two registries can be shared upon application, provided that ethical approval is obtained.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .